BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 28258988)

  • 1. Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients.
    Papadakis GZ; Mavroudis D; Georgoulias V; Souglakos J; Alegakis AK; Samonis G; Bagci U; Makrigiannakis A; Zoras O
    Growth Horm IGF Res; 2017 Apr; 33():28-34. PubMed ID: 28258988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.
    Xenidis N; Ignatiadis M; Apostolaki S; Perraki M; Kalbakis K; Agelaki S; Stathopoulos EN; Chlouverakis G; Lianidou E; Kakolyris S; Georgoulias V; Mavroudis D
    J Clin Oncol; 2009 May; 27(13):2177-84. PubMed ID: 19332733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer.
    Fürstenberger G; Senn E; Morant R; Bolliger B; Senn HJ
    Breast; 2006 Feb; 15(1):64-8. PubMed ID: 15998587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer.
    Holdaway IM; Mason BH; Lethaby AE; Singh V; Harvey VJ; Thompson PI; Evans BD
    ANZ J Surg; 2003 Nov; 73(11):905-8. PubMed ID: 14616567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.
    Apostolaki S; Perraki M; Pallis A; Bozionelou V; Agelaki S; Kanellou P; Kotsakis A; Politaki E; Kalbakis K; Kalykaki A; Vamvakas L; Georgoulias V; Mavroudis D
    Ann Oncol; 2007 May; 18(5):851-8. PubMed ID: 17301075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.
    Johansson H; Baglietto L; Guerrieri-Gonzaga A; Bonanni B; Mariette F; Macis D; Serrano D; Sandri MT; Decensi A
    Breast Cancer Res Treat; 2004 Nov; 88(1):63-73. PubMed ID: 15538047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.
    Schernhammer ES; Holly JM; Pollak MN; Hankinson SE
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):699-704. PubMed ID: 15767352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
    Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
    Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer.
    Xenidis N; Vlachonikolis I; Mavroudis D; Perraki M; Stathopoulou A; Malamos N; Kouroussis C; Kakolyris S; Apostolaki S; Vardakis N; Lianidou E; Georgoulias V
    Ann Oncol; 2003 Jun; 14(6):849-55. PubMed ID: 12796021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark.
    Kalledsøe L; Dragsted LO; Hansen L; Kyrø C; Grønbæk H; Tjønneland A; Olsen A
    Growth Horm IGF Res; 2019 Feb; 44():33-42. PubMed ID: 30622040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin may protect nondiabetic breast cancer women from metastasis.
    El-Haggar SM; El-Shitany NA; Mostafa MF; El-Bassiouny NA
    Clin Exp Metastasis; 2016 Apr; 33(4):339-57. PubMed ID: 26902691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer.
    Xenidis N; Perraki M; Apostolaki S; Agelaki S; Kalbakis K; Vardakis N; Kalykaki A; Xyrafas A; Kakolyris S; Mavroudis D; Georgoulias V
    Br J Cancer; 2013 Feb; 108(3):549-56. PubMed ID: 23329233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer.
    Tryfonidis K; Kafousi M; Perraki M; Apostolaki S; Agelaki S; Georgoulias V; Stathopoulos E; Mavroudis D
    Clin Breast Cancer; 2014 Dec; 14(6):442-50. PubMed ID: 24958324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes.
    Spiliotaki M; Mavroudis D; Kokotsaki M; Vetsika EK; Stoupis I; Matikas A; Kallergi G; Georgoulias V; Agelaki S
    Mol Oncol; 2018 Jan; 12(1):21-32. PubMed ID: 28766847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
    Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
    Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features.
    Rocha RL; Hilsenbeck SG; Jackson JG; Lee AV; Figueroa JA; Yee D
    J Natl Cancer Inst; 1996 May; 88(9):601-6. PubMed ID: 8609661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer.
    Baglietto L; English DR; Hopper JL; Morris HA; Tilley WD; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):763-8. PubMed ID: 17416768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer.
    Tas F; Karabulut S; Bilgin E; Tastekin D; Duranyildiz D
    Tumour Biol; 2014 Sep; 35(9):9303-9. PubMed ID: 24943688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.